Format

Send to

Choose Destination
Sci Rep. 2017 Mar 15;7:44275. doi: 10.1038/srep44275.

Correlations between TBL1XR1 and recurrence of colorectal cancer.

Author information

1
Department of General Surgery, Qilu Hospital Affiliated to Shandong University, Jinan, Shandong 250012, China.
2
Department of Respiratory Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China.
3
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, 100191, China.
4
302 Military Hospital of China, Beijing 100000, China.
5
Department of Gastrointestinal Surgery, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong 250012, China.
6
Department of Breast Surgery, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong 250012, China.

Abstract

More than 25% localized CRC patients died from post-operative metastasis, and risk of metastasis varies among individuals due to the high heterogeneity of CRC. Therefore, figuring out potential biomarkers for disease recurrence would be invaluable to improve the follow-up efficiency and clinical treatment. Transducin (β)-like 1 X-linked receptor 1 (TBL1XR1) is a core component of the nuclear receptor corepressor complex, which functions as a repressive coregulatory factor for multiple transcription factors. The clinical significance of TBL1XR1 in CRC hasn't been fully elucidated. In this study, we investigated the expression of TBL1XR1 in primary CRC tissues and liver metastases from TNM stage IV CRC patients, and found that its expression in primary tumor tissues was an independent prognostic factor for tumor recurrence. Thus, we enrolled another cohort including TNM stage I-III patients to further evaluate the relationship between TBL1XR1 expression and disease recurrence. Accordingly, high TBL1XR1 expression indicates poor disease-free survival of stage I-III CRC patients. Furthermore, we confirmed the importance of β-catenin signaling pathways in TBL1XR1-mediated CRC cell oncogenicity by clinical and cellular results. Our results emphasize the necessity of individual therapy decisions based on clinical biomarkers, especially for localized CRC patients who are not routinely treated with adjunctive chemotherapy.

PMID:
28295012
PMCID:
PMC5353619
DOI:
10.1038/srep44275
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center